Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer
Purpose. Patients with high-risk prostate cancer (PC) can be treated with high-dose intensity-modulated radiotherapy (IMRT) and long-term androgen deprivation (AD). In this paper we report on (i) late toxicity and (ii) biochemical (bRFS) and clinical relapse-free survival (cRFS) of this combined tre...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2012/368528 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566911964020736 |
|---|---|
| author | Valérie Fonteyne Nicolaas Lumen Geert Villeirs Piet Ost Gert De Meerleer |
| author_facet | Valérie Fonteyne Nicolaas Lumen Geert Villeirs Piet Ost Gert De Meerleer |
| author_sort | Valérie Fonteyne |
| collection | DOAJ |
| description | Purpose. Patients with high-risk prostate cancer (PC) can be treated with high-dose intensity-modulated radiotherapy (IMRT) and long-term androgen deprivation (AD). In this paper we report on (i) late toxicity and (ii) biochemical (bRFS) and clinical relapse-free survival (cRFS) of this combined treatment. Methods. 126 patients with high-risk PC (T3-4 or PSA >20 ng/mL or Gleason 8–10) and ≥24 months of followup were treated with high-dose IMRT and AD. Late toxicity was recorded. Biochemical relapse was defined as PSA nadir +2 ng/mL. Clinical relapse was defined as local failure or metastases. Results. The incidence of late grade 3 gastrointestinal and genitourinary toxicity was 2 and 6%, respectively. Five-year bRFS and cRFS were 73% and 86% respectively. AD was a significant predictor of bRFS (P=0.001) and cRFS (P=0.01). Conclusion. High-dose IMRT and AD for high-risk PC offers excellent biochemical and clinical control with low toxicity. |
| format | Article |
| id | doaj-art-a5ba995411a048b1afdb6c14f3b3fe77 |
| institution | Kabale University |
| issn | 1687-6369 1687-6377 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Urology |
| spelling | doaj-art-a5ba995411a048b1afdb6c14f3b3fe772025-02-03T01:02:48ZengWileyAdvances in Urology1687-63691687-63772012-01-01201210.1155/2012/368528368528Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate CancerValérie Fonteyne0Nicolaas Lumen1Geert Villeirs2Piet Ost3Gert De Meerleer4Department of Radiotherapy, Ghent University Hospital, 9000 Ghent, BelgiumDepartment of Urology, Ghent University Hospital, 9000 Ghent, BelgiumDepartment of Radiology, Ghent University Hospital, 9000 Ghent, BelgiumDepartment of Radiotherapy, Ghent University Hospital, 9000 Ghent, BelgiumDepartment of Radiotherapy, Ghent University Hospital, 9000 Ghent, BelgiumPurpose. Patients with high-risk prostate cancer (PC) can be treated with high-dose intensity-modulated radiotherapy (IMRT) and long-term androgen deprivation (AD). In this paper we report on (i) late toxicity and (ii) biochemical (bRFS) and clinical relapse-free survival (cRFS) of this combined treatment. Methods. 126 patients with high-risk PC (T3-4 or PSA >20 ng/mL or Gleason 8–10) and ≥24 months of followup were treated with high-dose IMRT and AD. Late toxicity was recorded. Biochemical relapse was defined as PSA nadir +2 ng/mL. Clinical relapse was defined as local failure or metastases. Results. The incidence of late grade 3 gastrointestinal and genitourinary toxicity was 2 and 6%, respectively. Five-year bRFS and cRFS were 73% and 86% respectively. AD was a significant predictor of bRFS (P=0.001) and cRFS (P=0.01). Conclusion. High-dose IMRT and AD for high-risk PC offers excellent biochemical and clinical control with low toxicity.http://dx.doi.org/10.1155/2012/368528 |
| spellingShingle | Valérie Fonteyne Nicolaas Lumen Geert Villeirs Piet Ost Gert De Meerleer Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer Advances in Urology |
| title | Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer |
| title_full | Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer |
| title_fullStr | Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer |
| title_full_unstemmed | Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer |
| title_short | Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer |
| title_sort | clinical results after high dose intensity modulated radiotherapy for high risk prostate cancer |
| url | http://dx.doi.org/10.1155/2012/368528 |
| work_keys_str_mv | AT valeriefonteyne clinicalresultsafterhighdoseintensitymodulatedradiotherapyforhighriskprostatecancer AT nicolaaslumen clinicalresultsafterhighdoseintensitymodulatedradiotherapyforhighriskprostatecancer AT geertvilleirs clinicalresultsafterhighdoseintensitymodulatedradiotherapyforhighriskprostatecancer AT pietost clinicalresultsafterhighdoseintensitymodulatedradiotherapyforhighriskprostatecancer AT gertdemeerleer clinicalresultsafterhighdoseintensitymodulatedradiotherapyforhighriskprostatecancer |